Zymeworks Crescita futura
Criteri Future verificati 3/6
Zymeworks prevede che gli utili e i ricavi cresceranno rispettivamente di 30.8% e 10.7% all'anno. Si prevede che l'EPS crescerà di 39.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 13.6% in 3 anni.
Informazioni chiave
30.8%
Tasso di crescita degli utili
39.42%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 23.4% |
| Tasso di crescita dei ricavi | 10.7% |
| Rendimento futuro del capitale proprio | 13.65% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 29 Apr 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
ZYME: Royalty Model Shift Will Rely On Upcoming HER2 Gastric Trial Data
Narrative Update on Zymeworks Analysts have lifted Zymeworks' implied price target range into the mid to high $40s, citing the $250m Royalty Pharma debt deal and a shift toward a more royalty focused model as key reasons for refining assumptions around profitability and a higher future P/E multiple. Analyst Commentary Recent Street research has been broadly constructive on Zymeworks, with several price target increases clustered in the mid to high $40s.ZYME: Royalty Model Outlook Will Hinge On Upcoming HER2 Gastric Cancer Data
Analysts have raised Zymeworks’ fair value estimate from about $36.46 to $40.08, citing higher price targets in the $46 to $48 range, supportive views on the $250m Royalty Pharma financing, and a shift toward a more royalty-focused business model. Analyst Commentary Recent Street research has focused on Zymeworks’ financing decisions, its pivot toward a royalty-driven model, and the pipeline events that could influence how investors think about execution and valuation.
ZYME: Royalty Model Shift And FY26 Catalysts Will Drive Future Upside
Analysts have lifted their Zymeworks price target range into the mid $40s, citing the $250m Royalty Pharma financing and the company's tilt toward a more royalty-focused model, along with upcoming clinical and R&D milestones, as key supports for the higher valuations. Analyst Commentary Bullish analysts are clustering around price targets in the mid US$40s, reflecting a view that the recent US$250m Royalty Pharma financing and the pivot toward royalties could support higher valuations if execution stays on track.ZYME: Royalty Model Shift And Debt Deal Will Drive Future Upside
Narrative Update: Zymeworks Analyst Price Target Shift The analyst price target for Zymeworks has moved from $48.27 to $55.34, with analysts pointing to the recent $250m Royalty Pharma debt deal, a more royalty-focused model, and upcoming clinical and R&D milestones as key factors supporting the higher valuation range cited in recent reports of $46 to $48. Analyst Commentary Bullish analysts are leaning into a more constructive view on Zymeworks, with several price targets now clustered in the mid to high US$40s range.ZYME: Cancer Trial Success And Royalty Potential Will Drive Future Upside
Analysts have raised their price target on Zymeworks from $42.00 to approximately $48.27, citing updated assumptions around revenue growth, profit margins and future P/E expectations. What's in the News Chief Financial and Business Officer Leone Patterson plans to leave Zymeworks in the first quarter of 2026, with her role ending January 9, 2026, and employment concluding January 31, 2026 (company announcement).ZYME: Royalty Model Will Be Supported By Upcoming HER2 Gastric Cancer Data
Analysts have raised their price targets on Zymeworks, with one firm moving to $40 from $37 and another to $25 from $17, citing the company's shift toward a royalty-focused model and expectations around upcoming HERIZON GEA-01 data as key drivers. Analyst Commentary Bullish Takeaways Bullish analysts point to the shift toward a royalty-focused model as a key reason for higher price targets, arguing that recurring royalty streams can support more visible revenue over time.
ADC And T Cell Engager Setbacks Will Test Reliance On Milestones Yet Offer Long-Term Upside
Catalysts About Zymeworks Zymeworks is a clinical stage biotechnology company focused on antibody drug conjugates, T cell engagers and partnered biologics for oncology and inflammatory diseases. What are the underlying business or industry changes driving this perspective?ZYME: Royalty Model Will Be Driven By Positive HER2 Gastric Cancer Data
Narrative Update Analysts have nudged their blended price target for Zymeworks higher from about $34.50 to roughly $35.62 as they factor in the company’s shift toward a royalty-focused model around zani, positive HERIZON-GEA data for Ziihera, and updated views on future profitability and P/E assumptions. Analyst Commentary Street research on Zymeworks is clustering around two main themes: the shift toward a royalty-focused model centered on zani, and the impact of recent clinical data for Ziihera and early pipeline assets.ZYME: Royalty Model And Cancer Data Will Drive Future Upside
Analysts have lifted their price targets on Zymeworks into a US$25 to US$42 range, citing the shift toward a royalty-focused model, positive HERIZON-GEA-01 data for Ziihera and Zani, and early but encouraging readouts for ZW191 and ZW251 as key drivers of their updated views. Analyst Commentary Bullish analysts are reacting positively to Zymeworks' shift toward a royalty-focused model and the recent clinical updates for Ziihera, Zani, ZW191, and ZW251.HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth
Jan 12ZYME: Royalty Aggregator Model And Cancer Data Will Drive Future Upside
Analysts have lifted their price targets on Zymeworks into a roughly US$25 to US$42 range, reflecting their views on the company’s shift toward a royalty-focused model, positive HERIZON-GEA-01 data around Ziihera and Zani, and early ZW191 results that feed into higher assumed profit margins and a richer future P/E multiple in updated models. Analyst Commentary Recent Street research on Zymeworks has been broadly constructive, with several firms revisiting their models after the shift toward a royalty-focused setup and fresh clinical data around Ziihera, Zani and ZW191.ZYME: Royalty Model And Cancer Data Will Drive Share Outperformance
The analyst fair value estimate for Zymeworks has been raised from $30.00 to $42.00 per share, as analysts point to stronger than expected HERIZON-GEA-01 efficacy data, an expanding royalty-driven model, and upgraded Street price targets as key drivers of higher growth and margin assumptions. Analyst Commentary Bullish analysts are increasingly framing Zymeworks as a higher quality growth story, citing a transition toward a recurring, royalty-driven revenue model and stronger than expected efficacy data from HERIZON GEA-01.ZYME: Royalty Model Will Benefit From Positive HER2 Gastric Cancer Data
Analysts nudged their fair value estimate for Zymeworks slightly higher, from $34.20 to $34.50. This reflects growing confidence that the company’s shift toward a royalty aggregator model, coupled with strong HERIZON-GEA-01 data for Ziihera and encouraging early ZW191 results, can drive faster revenue growth and improved profitability.ZYME: Recurring Royalty Revenue Will Drive Momentum After Positive Clinical Results
Zymeworks' analyst price target has surged from approximately $24.45 to $34.20 per share. This increase reflects analysts' optimism following the company's positive clinical trial results and strategic shift toward generating recurring royalty revenues.Zymeworks Inc.'s (NASDAQ:ZYME) Shares Climb 30% But Its Business Is Yet to Catch Up
Nov 18
Zymeworks Inc. (NASDAQ:ZYME) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 09ZYME: Encouraging Pipeline Data Will Drive Momentum Ahead Of Key Clinical Readouts
Analysts have raised their price target for Zymeworks from $23.68 to $24.45 per share. They cite increased confidence in the company's growth outlook following encouraging clinical data and expanding therapeutic opportunities.Analysts Raise Zymeworks Target on Pipeline Progress While Weighing Risks and Valuation Changes
Analysts have increased their price target for Zymeworks from $21.45 to $23.68 per share. They cite the company's differentiated therapies and upcoming clinical milestones as key drivers for the revised outlook.Oncology And Biologic Therapies Will Unlock Global Opportunities
Analysts have increased their price target for Zymeworks from $20.06 to $21.45, citing improving revenue growth forecasts, stronger projected profit margins, and growing confidence in the momentum of Zanidatamab in biliary tract cancer. Analyst Commentary Recent commentary from street research reflects a mix of optimism and caution surrounding Zymeworks, particularly as the company advances its lead asset, Zanidatamab, in the biliary tract cancer market.Oncology And Biologic Therapies Will Unlock Global Opportunities
Despite raised analyst confidence driven by positive clinical momentum for Zanidatamab and anticipated catalysts, Zymeworks’ consensus analyst price target has been modestly lowered from $21.05 to $20.06. Analyst Commentary Positive momentum for Zanidatamab in biliary tract cancer.Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 25% But Growth Is Lacking
Sep 07Zymeworks Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Aug 10There's Reason For Concern Over Zymeworks Inc.'s (NASDAQ:ZYME) Price
Jun 18Analysts Just Shipped A Stunning Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates
May 14Zymeworks: Poised For Growth With Platform Validation
Apr 28We're Hopeful That Zymeworks (NASDAQ:ZYME) Will Use Its Cash Wisely
Apr 16
Ziihera Launch And ZW251 IND Submission Will Broaden Treatment Options
Strategic focus on advanced programs and cost management aims to enhance resource efficiency and net margins through promising returns.Industry Analysts Just Upgraded Their Zymeworks Inc. (NASDAQ:ZYME) Revenue Forecasts By 13%
Mar 11Zymeworks Inc.'s (NASDAQ:ZYME) Business Is Yet to Catch Up With Its Share Price
Feb 28Zymeworks: Its Post-Approval Future
Feb 10Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule
Dec 19Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth
Dec 13Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking
Nov 08Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab
Nov 04Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Nov 03Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 184 | -2 | 20 | 35 | 8 |
| 12/31/2027 | 210 | -3 | -41 | -10 | 11 |
| 12/31/2026 | 298 | 129 | 105 | 74 | 12 |
| 12/31/2025 | 106 | -81 | -35 | -33 | N/A |
| 9/30/2025 | 134 | -63 | -66 | -64 | N/A |
| 6/30/2025 | 123 | -74 | -41 | -39 | N/A |
| 3/31/2025 | 93 | -114 | -79 | -76 | N/A |
| 12/31/2024 | 76 | -123 | -113 | -110 | N/A |
| 9/30/2024 | 62 | -114 | -59 | -55 | N/A |
| 6/30/2024 | 63 | -113 | -96 | -91 | N/A |
| 3/31/2024 | 50 | -126 | -77 | -73 | N/A |
| 12/31/2023 | 76 | -119 | -122 | -118 | N/A |
| 9/30/2023 | 462 | 205 | 192 | 195 | N/A |
| 6/30/2023 | 448 | 186 | 159 | 165 | N/A |
| 3/31/2023 | 446 | 173 | 108 | 116 | N/A |
| 12/31/2022 | 412 | 124 | 131 | 144 | N/A |
| 9/30/2022 | 30 | -224 | -252 | -234 | N/A |
| 6/30/2022 | 32 | -237 | -231 | -212 | N/A |
| 3/31/2022 | 28 | -240 | -224 | -207 | N/A |
| 12/31/2021 | 27 | -212 | -206 | -192 | N/A |
| 9/30/2021 | 22 | -211 | -199 | -190 | N/A |
| 6/30/2021 | 21 | -223 | -161 | -155 | N/A |
| 3/31/2021 | 31 | -194 | -161 | -155 | N/A |
| 12/31/2020 | 39 | -181 | -158 | -151 | N/A |
| 9/30/2020 | 25 | -215 | -147 | -140 | N/A |
| 6/30/2020 | 30 | -173 | -150 | -135 | N/A |
| 3/31/2020 | 26 | -163 | -113 | -98 | N/A |
| 12/31/2019 | 30 | -145 | -96 | -82 | N/A |
| 9/30/2019 | 57 | -64 | N/A | 5 | N/A |
| 6/30/2019 | 51 | -52 | N/A | 3 | N/A |
| 3/31/2019 | 65 | -29 | N/A | 20 | N/A |
| 12/31/2018 | 53 | -37 | N/A | 24 | N/A |
| 9/30/2018 | 74 | -13 | N/A | 13 | N/A |
| 6/30/2018 | 72 | -11 | N/A | 14 | N/A |
| 3/31/2018 | 52 | -16 | N/A | -5 | N/A |
| 12/31/2017 | 52 | -11 | N/A | 0 | N/A |
| 9/30/2017 | 4 | -55 | N/A | -47 | N/A |
| 6/30/2017 | 6 | -51 | N/A | -50 | N/A |
| 3/31/2017 | 11 | -47 | N/A | -41 | N/A |
| 12/31/2016 | 11 | -34 | N/A | -35 | N/A |
| 9/30/2016 | 10 | -30 | N/A | -32 | N/A |
| 12/31/2015 | 10 | -19 | N/A | -22 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che ZYME diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 3.4% ).
Guadagni vs Mercato: Si prevede che ZYME diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.
Guadagni ad alta crescita: Si prevede ZYME diventerà redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di ZYME ( 10.7% all'anno) crescerà più lentamente rispetto al mercato US ( 11.1% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di ZYME ( 10.7% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di ZYME sarà basso tra 3 anni ( 13.6 %).
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/03 23:21 |
| Prezzo dell'azione a fine giornata | 2026/05/01 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Zymeworks Inc. è coperta da 21 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| David Martin | Bloom Burton & Co. |
| Mayank Mamtani | B. Riley Securities, Inc. |